Entero Therapeutics, Inc. (GRDX) SEC Filings — 2024

Filings

• Entero Therapeutics Reports Financial Obligation Event — 8-K · Nov 27, 2024
• Entero Therapeutics Enters Material Definitive Agreement — 8-K · Nov 13, 2024
• Entero Therapeutics Q3: Assets $4.74M, Liabilities $1.56M — 10-Q · Nov 13, 2024
• Entero Therapeutics Reports Q2 Loss, Cash Position — 10-Q · Oct 21, 2024
• Entero Therapeutics Faces Delisting Notice — 8-K · Sep 11, 2024
• Entero Therapeutics Files 8-K — 8-K · Sep 10, 2024
• Entero Therapeutics to Acquire 03 Life Sciences — 8-K · Sep 3, 2024
• Entero Therapeutics Changes Auditors Amidst Accounting Disagreements — 8-K · Aug 29, 2024
• Entero Therapeutics Faces Delisting Concerns — 8-K · Aug 23, 2024
• Entero Therapeutics Appoints New CEO, Dr. David J. Mazzo — 8-K · Aug 22, 2024
• Entero Therapeutics Changes Auditors Amidst Disagreement — 8-K · Aug 15, 2024
• Entero Therapeutics Files 8-K: Delisting Risk, Exec Changes — 8-K · Aug 7, 2024
• Entero Therapeutics Files 8-K — 8-K · Jul 31, 2024
• Entero Therapeutics Appoints New CMO, Director — 8-K · Jul 23, 2024
• Entero Therapeutics Enters Material Definitive Agreement — 8-K · Jul 11, 2024
• Entero Therapeutics Appoints New CMO, Director — 8-K · Jun 20, 2024
• Entero Therapeutics Appoints New Auditor, Dismisses BDO USA — 8-K · Jun 5, 2024
• Entero Therapeutics Files 8-K/A Amendment — 8-K/A · May 30, 2024
• First Wave BioPharma Files 8-K with Corporate Updates — 8-K · May 16, 2024
• First Wave BioPharma Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024
• First Wave BioPharma Files 8-K: Material Agreement & Equity Sales — 8-K · May 13, 2024
• First Wave BioPharma Files Amendment for IMGX Merger Financials — 8-K/A · May 8, 2024
• First Wave BioPharma Files 2023 10-K, Details Financials and Strategic Events — 10-K · Mar 29, 2024
• First Wave BioPharma Faces Delisting Concerns — 8-K · Mar 22, 2024
• First Wave BioPharma Files 8-K — 8-K · Mar 18, 2024
• First Wave BioPharma Secures $1.5M Private Placement, CMO Departs — 8-K · Mar 14, 2024
• First Wave BioPharma Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 5, 2024
• First Wave Biopharma, Inc. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• First Wave BioPharma Files 8-K for General Disclosure — 8-K · Jan 4, 2024